<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020445</url>
  </required_header>
  <id_info>
    <org_study_id>BekesCCH</org_study_id>
    <nct_id>NCT04020445</nct_id>
  </id_info>
  <brief_title>Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes</brief_title>
  <official_title>Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bekes County Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Debrecen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bekes County Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines prospectively the safety and efficacy of switching from multiple daily
      insulin injections (MDI) to once daily IDegLira (insulin degludec and liraglutide fix ratio
      combination), a fixed-ratio combination of insulin degludec and liraglutide, in relatively
      well controlled (HbA1c&lt;7.5%) subjects with type 2 diabetes using low total daily insulin dose
      (TDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetic patients suffering from severe hyperglycemia are often apply multiple daily
      insulin injections (MDI). If glucose toxicity resolves, the regimen may potentially be
      simplified, but there are no specific guidelines regarding this and a lot of patients are
      left on MDI.

      The Investigators aimed to examine prospectively the safety and efficacy of switching from
      MDI to once daily IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, in
      relatively well controlled (HbA1c&lt;7.5%) subjects with type 2 diabetes using low total daily
      insulin dose (TDD).

      The investigators hypothesize that in everyday clinical practice switching from low dose MDI
      to IDegLira in patients of different ages with well-controlled (or overcontrolled) type 2
      diabetes is safe, may induce weight loss and result in similar or better glycemic control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reaching HbA1c&lt;7% and HbA1c&lt;6.5%</measure>
    <time_frame>it is checked at baseline and at 3, 6, 9 and 12 months</time_frame>
    <description>HbA1c is measuerd by laboratory blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in body weight from baseline to 3, 6, 9 and 12 months</measure>
    <time_frame>it is checked at baseline and at 3, 6, 9 and 12 months</time_frame>
    <description>body weight is measured at the diabetes ambulance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in risk of hypoglycemia from baseline to 3, 6, 9 and 12 months</measure>
    <time_frame>it is checked at baseline and at 3, 6, 9 and 12 months</time_frame>
    <description>hypoglycemia risk is assessed by analysing the patients' diary</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HBA1c</condition>
  <condition>Body Weight</condition>
  <condition>Hypoglycemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>de-escalation of complex insulin regimens</intervention_name>
    <description>complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Well-controlled or overtreated adult type 2 diabetic patients using relatively low dose
        MDI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetic (T2D) patients &gt;18 years old

          -  detectable random, non-fasting serum C-peptide levels

          -  HbA1c=&lt; 7.5%

          -  treated with MDI (with stable daily doses of insulin at least for 90 days prior to
             baseline visit)

          -  using relatively low total daily insulin dose (TDD), at baseline visit low TDD is
             defined as TDD&lt;70 IU/day and TDD&lt;0.6 IU/kg/day at the same time.

        Exclusion Criteria:

          -  Type 1 diabetes

          -  treatment of T2D with any medication for diabetes other than insulin or metformin
             during 90 days before baseline visit

          -  active cancer

          -  anaemia (haemoglobin &lt;100g/l)

          -  acute or chronic kidney disease with an estimated glomerular filtration rate &lt;30
             mL/min/1.73 m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zoltán J Taybani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bekes County Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zoltán J Taybani, MD</last_name>
    <phone>+3666555562</phone>
    <email>taybaniz@bmkk.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zoltán Taybani</name>
      <address>
        <city>Békéscsaba</city>
        <state>Békés</state>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán J Taybani, MD</last_name>
      <phone>+3666555562</phone>
      <email>taybaniz@bmkk.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <results_reference>
    <citation>Taybani Z, Bótyik B, Katkó M, Gyimesi A, Várkonyi T. Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. Diabetes Ther. 2019 Oct;10(5):1869-1878. doi: 10.1007/s13300-019-0673-8. Epub 2019 Jul 25.</citation>
    <PMID>31347100</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bekes County Central Hospital</investigator_affiliation>
    <investigator_full_name>Zoltán Taybani</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>iDegLira</keyword>
  <keyword>deintensification</keyword>
  <keyword>overtreatment</keyword>
  <keyword>simplification</keyword>
  <keyword>type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

